文献速递妇科

腹水量对卵巢癌临床结局的影响:一项队列研究

Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study.
PubMed 文献 · Gynecol Oncol · 2017-06-16

该队列研究在单中心685例卵巢癌患者中分析腹水量与结局的关系,发现每升腹水与更短的无进展生存期(PFS)和总生存期(OS)相关;腹水量大于中位数2000mL者PFS和OS显著更短,腹水存在与达到理想肿瘤细胞减灭术的能力呈负相关,小鼠模型结果与患者相关性结果一致。

要点

  • 每升腹水与更短PFS(HR=1.12,95%CI:1.07-1.17)和OS(HR=1.12,95%CI:1.07-1.17)相关。
  • 腹水量大于中位数2000mL者PFS为14.5个月 vs 22.7个月,OS为27.7个月 vs 42.9个月,均p<0.001。
  • 调整分期后,腹水存在与达到理想肿瘤细胞减灭术的能力呈负相关。

核心结论

  • 卵巢癌初诊时腹水量与更差的无进展生存期和总生存期相关。
  • 大量腹水对预后影响的效应可能部分与完全切除肿瘤(R0)的可能性降低有关。
  • 若这些发现能在独立研究中得到证实,应考虑将诊断时大量腹水的存在纳入卵巢癌分期标准。

研究设计与样本

  • 队列研究,从单中心整理数据库获取卵巢癌患者的临床病理特征。
  • 共识别685例患者,58%在初次手术时存在腹水。
  • 腹水量以2000mL为界进行二分类,比较高腹水量与低腹水量。
  • 另在上皮性卵巢癌同系小鼠模型中评估腹腔注射小鼠无细胞腹水与生理盐水的影响。

主要发现

  • 每升腹水与更短PFS相关(HR=1.12,95%CI:1.07-1.17),与更短OS相关(HR=1.12,95%CI:1.07-1.17)。
  • 腹水量大于中位数2000mL者PFS为14.5个月 vs 22.7个月(p<0.001),OS为27.7个月 vs 42.9个月(p<0.001)。
  • 调整分期后,腹水存在与达到理想肿瘤细胞减灭术的能力呈负相关。
  • 小鼠模型中腹腔注射小鼠无细胞腹水加速卵巢癌进展,与患者中的相关性结果一致。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the impact of ascites volume on ovarian cancer outcomes. METHODS: Clinicopathologic features of a cohort of patients with ovarian cancer were obtained from a curated database at a single institution. Progression free survival (PFS) and overall survival (OS) were recorded. Ascites volume at primary surgery was dichotomized at 2000mL and comparisons for high and low volume ascites were made. Additionally, to elucidate interactions between ascites and ovarian tumor progression, we evaluated the effect of intraperitoneal administrations of murine cell-free ascites versus saline in a syngeneic mouse model of epithelial ovarian cancer. RESULTS: Out of 685 patients identified, 58% had ascites present at the time of initial surgery. Considering the volume of ascites continuously, each liter of ascites was associated with shorter PFS (HR=1.12, 95% CI: 1.07-1.17) and OS (HR=1.12, 95%CI: 1.07-1.17). Patients with ascites greater than the median of 2000mL had significantly shorter PFS (14.5months vs. 22.7months; p<0.001) and OS (27.7months vs. 42.9months; p<0.001). After adjusting for stage, presence of ascites was inversely associated with ability to achieve optimal cytoreductive surgery. Consistent with these correlative results in patients, intraperitoneal administrations of murine cell-free ascites accelerated ovarian cancer progression in mice. CONCLUSIONS: The volume of ascites at initial diagnosis of ovarian cancer correlated with worse PFS and OS. The effect of large volume on prognosis is likely to be in part related to reduced likelihood for complete resection of tumor (R0). If these findings are confirmed in independent studies, consideration should be made to add the presence of large volume ascites at diagnosis to the staging criteria for ovarian cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Szender JB, Emmons T, Belliotti S, et al. Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study. Gynecol Oncol. 2017. PMID: 28624153. doi:10.1016/j.ygyno.2017.06.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。